-
The American Society of Echocardiography (ASE) has recommended that quantitative techniques be used to assess the severity of mitral regurgitation (MR) by echocardiography.
-
Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.
-
-
The Rate Control Efficacy in Permanent Atrial Fibrillation (RACE II) study compared two different strategies for rate control in patients with permanent atrial fibrillation.
-
The number of patients with implantable pacemakers and implantable defibrillators has increased markedly in recent years. Unfortunately, cardiac rhythm device (CRM)-related infections have also increased, and management of these infections is often problematic.
-
Little is known about the least common of left ventricular (LV) remodeling abnormalities, low ejection fraction (EF) with no cavity dilation or non-dilated cardiomyopathy.
-
Surgical aortic valve replacement (SAVR) remains the gold standard treatment for calcific aortic stenosis (AS). However, AS is predominantly a disease of the elderly and, thus, many patients have significant comorbidities that make SAVR very high risk.
-
Health care clinicians and organizations likely will find that the new health care reform bill's positive features outweigh its drawbacks, experts say.
-
-
The single author of this small pilot study concludes that 50 mg of 5-HTP taken three times a day for 4 weeks is ineffective against menopausal hot flashes. The paper is disappointing in many ways, however, and readers might question whether the actual reason behind the trial was indeed to test 5-HTP.
